AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Atrial fibrillation (AF) is highly prevalent with a lifetime risk of about 1 in 3–5 individuals after
the age of 45 years. Between 2010 and 2019, the global prevalence of AF has risen …

Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation
experience cardiovascular complications. Additional treatments are needed to reduce these …

Heart failure is a substantial and escalating global health challenge, affecting millions
worldwide. This complex syndrome arises from diverse etiologies, encompassing ischemic …

The importance of magnesium (Mg2+), a micronutrient implicated in maintaining and
establishing a normal heart rhythm, is still controversial. It is known that magnesium is the …

SciELO - Brazil - Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com
Cardiomiopatia da Doença de Chagas – 2023 Diretriz da SBC sobre Diagnóstico e Tratamento …

Background: Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …

Aims Management of patients with atrial fibrillation (AF) and concomitant heart failure (HF)
remains complex. The Antwerp score, based on four parameters [QRS> 120 ms (2 points) …

Background Atrial fibrillation (AF) is one of the most common arrhythmia in clinical practice,
and atrial fibrosis is the important mediator in AF. LncRNA HOTAIR was reported to be up …

Atrial fibrillation (AF) and heart failure (HF) frequently coexist and complicate the course of
treatment of each other. AF with rapid ventricular conduction can lead to tachycardia …